Antithrombin

From Wikipedia, the free encyclopedia

(Redirected from Antithrombin III)
Jump to: navigation, search


Serpin peptidase inhibitor, clade C (antithrombin), member 1
Antithrombin dimer drawn from PDB 1E03.
Available structures: 1ant, 1ath, 1azx, 1br8, 1dzg, 1dzh, 1e03, 1e04, 1e05, 1jvq, 1lk6, 1nq9, 1oyh, 1r1l, 1sr5, 1t1f, 1tb6, 2ant, 2b4x, 2b5t, 2beh, 2gd4
Identifiers
Symbol(s) SERPINC1; AT3; ATIII; MGC22579
External IDs OMIM: 107300 MGI88095 Homologene20139
RNA expression pattern

More reference expression data

Orthologs
Human Mouse
Entrez 462 11905
Ensembl ENSG00000117601 ENSMUSG00000026715
Uniprot P01008 Q543J5
Refseq NM_000488 (mRNA)
NP_000479 (protein)
NM_080844 (mRNA)
NP_543120 (protein)
Location Chr 1: 172.14 - 172.15 Mb Chr 1: 162.82 - 162.84 Mb
Pubmed search [1] [2]

Antithrombin is a small protein molecule that inactivates several enzymes of the coagulation system. It is a glycoprotein produced by the liver and consists of 432 amino acids. It contains three disulfide bonds and a total of four possible glycosylation sites. α-antithrombin is the dominant form of antithrombin found in blood plasma and has an oligosaccharide occupying each of its four glycosylation sites. A single glycosylation site remains consistently un-occupied in the minor form of antithrombin, β-antithrombin.[1]

Contents

Antithrombin has a half life in blood plasma of around 3 days.[2] The normal antithrombin concentration in human blood plasma is approximately 0.12 mg/ml, which is equivalent to a molar concentration of 2.3 μM.[3] Antithrombin has been isolated from the plasma of a large number of species additional to humans.[4] As deduced from protein and cDNA sequencing, cow, sheep, rabbit and mouse antithrombins are all 433 amino acids in length, which is one amino acid longer than human antithrombin III. The extra amino acid is thought to occur at amino acid position 6. Cow, sheep, rabbit, mouse and human antithrombins share between 84 and 89% amino acid sequence identity.[5] They all have four potential N-glycosylation sites. These occur at asparagine (Asn) amino acid numbers 96, 135, 155 and 192 in humans and at similar amino acid numbers in other species. All these sites are occupied by covalently attached oligosaccharide side chains in the predominant form of human antithrombin, α-antithrombin. The potential glycosylation site at asparagine 135 is not occupied in a minor form of antithrombin, β-antithrombin.[6] Shown below are the location of the four potential glycosylation sites within the tertiary structure of an antithrombin monomer, as taken from the protein data bank file 2ANT. In this structure only Asn 155 is glycosylated by the addition of a single N-acetylglucosamine residue.

Antithrombin is a serpin (serine protease inhibitor). The physiological target proteases of antithrombin are those of the intrinsic coagulation system, namely the activated forms of Factor X (Xa), Factor IX (IXa), Factor VII (VIIa), Factor XI (XIa), Factor XII (XIIa) and Factor II (thrombin) (IIa). Protease inactivation results as a consequence of the trapping the protease in an equimolar complex with antithrombin in which the active site of the protease enzyme is inaccessible to its usual substrate.[5] The formation of an antithrombin-protease complex involves an interaction between the protease and a specific reactive peptide bond within antithrombin. In human antithrombin this bond is between arginine (arg) 393 and serine (ser) 394.[5] As shown below the reactive arg 393 - ser 394 bond is located on an exposed loop at the surface of the molecule. This loop is termed the reactive site loop.

It is thought the trapping of protease enzymes in inactive antithrombin-protease complexes results as a consequence of their attack of the reactive bond. Where the attack of a similar bond within their normal substrate results in its rapid proteolytic cleavage, on initiating an attack on the antithrombin reactive bond the antithrombin inhibitor is activated to trap the enzyme at an intermediate stage during the proteolytic process. Given time thrombin is able to cleave the reactive bond within antithrombin and an inactive thrombin-antithrombin complex will dissociate, however the time it takes for this to occur may be greater than 3 days.[7]

The rate of antithrombin's inhibition of protease activity is greatly enhanced by its additional binding to heparin.

Antithrombin deficiency is a rare hereditary disorder that generally comes to light when a patient suffers recurrent venous thrombosis and pulmonary embolism.

Renal losses of antithrombin account for an increased risk of thrombosis in patients with nephrotic syndrome.

The gene for antithrombin is located on the first chromosome, locus 1q23-q25.1.

Antithrombin is officially called antithrombin III and is a member of a larger family of antithrombins (numbered I, II etc. to VI). All are serpins. Only AT III (and possibly AT I) is medically significant, with AT III generally referred to as antithrombin.

  1. ^ Bjork, I; Olson, JE (1997). Antithrombin, A bloody important serpin (in Chemistry and Biology of Serpins). Plenum Press, 17-33. ISBN 0-306-45698-2. 
  2. ^ Collen DJ, Schetz F. et al. (1977). "Metabolism of antithrombin III (heparin cofactor) in man: Effects of venous thrombosis of heparin administration". Eur. J. Clin. Invest 7: 27-35. PMID 65284. 
  3. ^ Conrad J, Brosstad M. et al. (1983). "Molar antithrombin concentration in normal human plasma". Haemostasis 13: 363-368. PMID 6667903. 
  4. ^ Jordan RE. (1983). "Antithrombin in vertebrate species: Conservation of the heparin-dependent anticoagulant mechanism". Arch. Biochem. Biophys 227: 587-595. PMID 6607710. 
  5. ^ a b c Olson ST, Bjork I. (1994). "Regulation of thrombin activity by antithrombin and heparin". Sem. Thromb. Hemost. 20 (4): 373-409. PMID 7899869. 
  6. ^ Brennan SO, George PM, Jordan, RE. (1987). "Physiological variant of antithrombin-III lacks carbohydrate side chain at Asn 135". FEBS Lett 219: 431-436. PMID 3609301. 
  7. ^ Danielsson A and Bjork, I (1980). "Slow, spontaneous dissociation of the antithrombin-thrombin complex produces a proteolytically modified form of the inhibitor". FEBS Lett 119: 241-244. PMID 7428936. 

Advanced Search
Included Web Search Engines


Safe Search

close

Top Matching Results

Occasionally Search.com will highlight specialized results that are based on the context of your query. Examples of specialized results include specific links to news, images, or video.

Top Matching Results may highlight information from other Search.com pages, content from the CNET Network of sites, or third party content. The listings are based purely on relevance. Search.com does not receive payment for listings in this section but our partners that provide this data may get paid for listing these products.

Sponsored Links

This section contains paid listings which have been purchased by companies that want to have their sites appear for specific search terms and related content. These listings are administered, sorted and maintained by a third party and are not endorsed by Search.com.

Search Results

Search.com sends your search query to several search engines at one time and integrates the results into one list which has been sorted by relevance using Search.com's proprietary algorithm. You can customize the list of search engines included in your metasearch from the preferences.

The search engines that are used in your metasearch may allow companies to pay to have their Web sites included within the results. To view the Paid Inclusion policy for a specific search engine, please visit their Web site. Search.com does not accept payment or share revenue with any search engine partner for listings in this section.